{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:57:01Z","timestamp":1771991821825,"version":"3.50.1"},"reference-count":0,"publisher":"Akademiai Kiado Zrt.","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["EuJMI"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:p>We compared the analytical and clinical performance of cobas<jats:sup>\u00ae<\/jats:sup> CT\/NG for use on the cobas<jats:sup>\u00ae<\/jats:sup> 6800\/8800 Systems with the cobas<jats:sup>\u00ae<\/jats:sup> 4800 CT\/NG Test from urogenital and extragenital specimens in over 12,000 specimens from both male and female subjects in Germany and the United States. The analytical sensitivity was \u226440 EB\/ml for <jats:italic>Chlamydia trachomatis<\/jats:italic> (CT) and \u22641 CFU\/ml for <jats:italic>Neisseria gonorrhoeae<\/jats:italic> (NG). Using clinical specimens, the overall percent agreement with the cobas<jats:sup>\u00ae<\/jats:sup> 4800 CT\/NG Test was &gt;98.5%. Across urogenital specimens, there were 93 discrepant specimens; 76 (93.8%) of 81 CT discrepant specimens were 6800+\/4800\u2212 and 10 (83.3%) of 12 NG discrepant specimens were 6800+\/4800\u2212. Sequencing verified CT results for 45 (61.6%) of 73 samples positive by 6800 and 1 (20%) of 5 positive by 4800. Similarly, 7 (70.0%) of 10 NG samples positive by 6800 and 1 of 2 positive by 4800 were confirmed by sequencing. Among discrepant extragenital specimens (all 6800+\/4800\u2212), 7 (50%) of 14 oropharyngeal and 23 (76.7%) of 30 anorectal CT discordant samples were confirmed as CT positive by sequencing; all 8 anorectal and 20 (90.9%) of 22 oropharyngeal NG discordant results were also confirmed as NG positive. In conclusion, cobas<jats:sup>\u00ae<\/jats:sup> CT\/NG for use on the cobas<jats:sup>\u00ae<\/jats:sup> 6800\/8800 Systems provides high-throughput automated solutions for sexually transmitted infection (STI) screening programs.<\/jats:p>","DOI":"10.1556\/1886.2017.00018","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T13:07:21Z","timestamp":1505135241000},"page":"176-186","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":20,"title":["High-throughput testing of urogenital and extragenital specimens for detection of Chlamydia trachomatis and Neisseria gonorrhoeae with cobas\u00ae CT\/NG"],"prefix":"10.1556","volume":"7","author":[{"given":"Elizabeth M.","family":"Marlowe","sequence":"first","affiliation":[{"name":"Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hardy","sequence":"additional","affiliation":[{"name":"Development, Roche Molecular Diagnostics, Inc., Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Krevolin","sequence":"additional","affiliation":[{"name":"Development, Roche Molecular Diagnostics, Inc., Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gohl","sequence":"additional","affiliation":[{"name":"Bioscientia, Ingelheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Bertram","sequence":"additional","affiliation":[{"name":"Amedes MVZ Wagnerstibbe f\u00fcr Laboratoriumsmedizin, H\u00e4mostaseologie, Humangenetik und Mikrobiologie, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Arcenas","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Seiverth","sequence":"additional","affiliation":[{"name":"Development, Roche Molecular Diagnostics, Rotkreuz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Schneider","sequence":"additional","affiliation":[{"name":"Development, Roche Molecular Diagnostics, Rotkreuz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Liesenfeld","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","container-title":["European Journal of Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/7\/3\/article-p176.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/7\/3\/article-p176.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/7\/3\/article-p176.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T16:40:00Z","timestamp":1704300000000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/7\/3\/article-p176.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":0,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/1886.2017.00018","relation":{},"ISSN":["2062-8633"],"issn-type":[{"value":"2062-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}